CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenues:
Revenues	$ 1,952.0	$ 1,577.8	$ 3,780.2	$ 2,950.4
Expenses:
Research and development	722.0	885.5	1,305.9	1,371.6
Selling, general, and administrative	348.3	294.6	715.6	585.7
Other operating (income) expense, net	(50.2)	(63.7)	(90.6)	(120.4)
Total expenses	1,295.6	1,262.2	2,423.7	2,154.8
Income from operations	656.4	315.6	1,356.5	795.6
Other income (expense):
Other income (expense), net	272.2	(82.9)	246.8	(9.1)
Interest expense	(9.7)	(8.0)	(15.8)	(15.7)
Total other income (expense)	262.5	(90.9)	231.0	(24.8)
Income before income taxes	918.9	224.7	1,587.5	770.8
Income tax expense	21.6	31.6	65.6	116.6
Net income	$ 897.3	$ 193.1	$ 1,521.9	$ 654.2
Net income per share - basic (in dollars per share)	$ 8.19	$ 1.77	$ 13.87	$ 6.00
Net income per share - diluted (in dollars per share)	$ 7.61	$ 1.68	$ 13.03	$ 5.69
Weighted average shares outstanding - basic (in shares)	109.6	109.2	109.7	109.1
Weighted average shares outstanding - diluted (in shares)	117.9	114.6	116.8	115.0
Statements of Comprehensive Income
Net income	$ 897.3	$ 193.1	$ 1,521.9	$ 654.2
Other comprehensive income (loss), net of tax:
Unrealized gain on debt securities	44.6	14.4	15.8	30.5
Unrealized loss on cash flow hedges	0.0	(1.4)	(1.4)	(2.4)
Comprehensive income	941.9	206.1	1,536.3	682.3
Product
Revenues:
Revenues	1,226.9	1,205.3	2,463.6	2,309.7
Expenses:
Cost of goods sold	102.5	67.0	181.3	137.9
Collaboration and contract manufacturing
Expenses:
Cost of goods sold	173.0	78.8	311.5	180.0
Sanofi | Product and service, other
Revenues:
Revenues	269.1	75.8	516.0	57.8
Bayer | Product and service, other
Revenues:
Revenues	244.2	277.2	525.6	541.2
Other | Product and service, other
Revenues:
Revenues	$ 211.8	$ 19.5	$ 275.0	$ 41.7